Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
Free Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank25
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P25
Within normal range
vs 3Y Ago
-2.8x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-66.50%
2024-276.18%
2023193.56%
202223.44%
20210.00%